<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157588">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048138</url>
  </required_header>
  <id_info>
    <org_study_id>CEP0560/05</org_study_id>
    <nct_id>NCT01048138</nct_id>
  </id_info>
  <brief_title>Use of Biperiden for the Prevention of Post-traumatic Epilepsy</brief_title>
  <official_title>Use of Biperiden as a Disease Modifying Agent After Traumatic Brain Injury: a Placebo Controlled, Randomized, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cristália Produtos Químicos Farmacêuticos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no AED or medication that has been demonstrated to affect the development of
      post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic
      receptor, that is widely used as an anti Parkinson drug. The investigators data with animal
      models of epilepsy indicate that anti-muscarinic agents might affect the natural course of
      the disease in the case of post-traumatic epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset of post-traumatic epilepsy</measure>
    <time_frame>12 months after hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of post-traumatic epilepsy</measure>
    <time_frame>24 months after hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Measured at 12 and 24 month after hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive level</measure>
    <time_frame>Measured at 12 and 24 month after hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Biperiden Lactate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg IV(in the vein)every 6 hours for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5mg IV(in the vein)every 6 hours for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biperiden Lactate</intervention_name>
    <arm_group_label>Biperiden Lactate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 18 and 75 year of age

          -  patients with a diagnosis of severe TBI admitted to an emergency unit within 6 hours
             of the accident, regardless of the accident

          -  brain CT scan with signs of acute intraparenchymatous contusion

          -  signed informed consent (possibly by a relative)

        Exclusion Criteria:

          -  malignant neoplasia and other severe comorbidities

          -  neurodegenerative disorders

          -  cerebrovascular accident in the previous 6 months

          -  record of convulsive seizures or use of anti-epileptic medication

          -  pregnancy

          -  concomitant use of the other anticholinergic medications

          -  presence of any factor that may contraindicate the use of biperiden

          -  participation in other clinical trial

          -  alcohol intoxication will not lead to exclusion of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Loduca</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luiz Mello</last_name>
    <phone>5511-55792033</phone>
    <email>lemello@unifesp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal University of São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz EM Mello</last_name>
      <phone>55-11-55792033</phone>
      <email>lemello@unifesp.br</email>
    </contact>
    <investigator>
      <last_name>Luiz EM Mello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>January 12, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Luiz Eugenio Mello</investigator_full_name>
    <investigator_title>M.D.Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Biperiden</keyword>
  <keyword>Post-traumatic Epilepsy</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Epilepsy, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Biperiden lactate</mesh_term>
    <mesh_term>Biperiden</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
